Sun Hee Kim, MD
Endocrinology · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 5
- 2 carriers
- Office
- 1
Offices
1 location · Stanford Health Care · 3,152 clinicians in this group
Looking this up.
Hospitals listed: Stanford Health Care. That is not proof they admit you there this week.
Plans that list them
5 plans · 2 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Kim’s office at (650) 723-4000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
5 of 5 plans
| SCAN Balance (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Classic (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN MyChoice (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
California Medical Board record
Licence A75251 · Current
Licensed to practise in California · since 2001 · expires 2028-07-31 · University of California, San Diego School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$44,876
Medicare paid this office $44,876 for 153 people. Most of that is long return visits and Botox.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 66 | $11,480 | $109 |
| Long return visit (40+ min) | 61 | $11,251 | $115 |
| Long return visit (40+ min) | 37 | $9,398 | $162 |
| Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report | 62 | $3,550 | $30 |
| Return visit (30+ min) | 35 | $3,503 | $81 |
See all 7 services
| Return visit (30+ min) | 66 | $11,480 | $109 |
| Long return visit (40+ min) | 61 | $11,251 | $115 |
| Long return visit (40+ min) | 37 | $9,398 | $162 |
| Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report | 62 | $3,550 | $30 |
| Return visit (30+ min) | 35 | $3,503 | $81 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 44 | $839 | $15 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 38 | $659 | $15 |
Who their Medicare patients are
153 Original Medicare patients in 2024. Average age 73 · Under 65 14% · 85 and older 11% · Women 54% · Also on Medicaid 32% · Health risk score 1.66. Above the middle of the specialty; the typical endocrinology clinician is at 1.46.
Conditions among them: High blood pressure 75% · Diabetes 75% · Chronic kidney disease 47% · Coronary heart disease 40% · Heart failure 24% · Cancer 20% · Atrial fibrillation 16% · Depression 14% · COPD 11%.
The office billed $213,134, Medicare allowed $61,626 and paid $44,876; for 564 services of 13 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 153 | 564 | 73 | 1.66 | $213,134 | $44,876 |
| 2023 | 148 | 465 | 72 | 1.62 | $201,325 | $38,327 |
| 2022 | 181 | 589 | 71 | 2.06 | $255,615 | $49,338 |
| 2021 | 165 | 426 | 71 | 1.92 | $197,205 | $40,122 |
| 2020 | 153 | 379 | 70 | 1.96 | $134,691 | $26,611 |
| 2019 | 120 | 249 | 70 | 1.65 | $28,910 | $17,174 |
| 2018 | 124 | 298 | 68 | 1.87 | $34,444 | $18,966 |
| 2017 | 117 | 308 | 67 | 1.87 | $52,205 | $19,846 |
| 2016 | 137 | 348 | 68 | 2.26 | $71,065 | $22,693 |
| 2015 | 125 | 347 | 69 | 1.98 | $78,673 | $25,786 |
| 2014 | 89 | 232 | 67 | 1.97 | $58,354 | $18,963 |
| 2013 | 94 | 269 | 68 | 1.86 | $68,296 | $22,333 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 5 services
| Long return visit (40+ min) | 87 | $18,350 | $120 |
| Return visit (30+ min) | 90 | $11,335 | $80 |
| Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report | 56 | $3,753 | $31 |
| New patient visit (60+ min) | 13 | $2,004 | $154 |
| Telephone medical discussion with physician, 21-30 minutes | 14 | $1,351 | $75 |
2022: 7 services
| Long return visit (40+ min) | 91 | $20,454 | $127 |
| Return visit (30+ min) | 80 | $10,709 | $80 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 30 | $5,718 | $65 |
| Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report | 51 | $3,169 | $31 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 22 | $2,643 | $120 |
| Telephone medical discussion with physician, 21-30 minutes | 17 | $2,097 | $84 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 16 | $627 | $35 |
2021: 7 services
| Long return visit (40+ min) | 83 | $17,250 | $126 |
| Return visit (30+ min) | 94 | $12,514 | $80 |
| New patient visit (60+ min) | 18 | $2,560 | $142 |
| Telephone medical discussion with physician, 21-30 minutes | 21 | $2,337 | $81 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 13 | $1,793 | $66 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 12 | $1,503 | $125 |
| Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report | 21 | $727 | $33 |
2020: 7 services
| Return visit (30+ min) | 101 | $12,431 | $66 |
| Telephone medical discussion with physician, 21-30 minutes | 30 | $2,658 | $74 |
| Long return visit (40+ min) | 16 | $2,083 | $99 |
| New patient visit (45+ min) | 17 | $1,672 | $98 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 12 | $1,658 | $128 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 14 | $1,570 | $37 |
| Return visit (30+ min) | 20 | $1,282 | $64 |
2019: 3 services
| Return visit (30+ min) | 102 | $12,959 | $64 |
| Long return visit (40+ min) | 16 | $2,142 | $93 |
| New patient visit (45+ min) | 17 | $1,735 | $102 |
2018: 3 services
| Return visit (30+ min) | 102 | $14,890 | $62 |
| New patient visit (45+ min) | 13 | $1,499 | $115 |
| Long return visit (40+ min) | 13 | $825 | $55 |
2017: 3 services
| Return visit (30+ min) | 96 | $14,936 | $62 |
| New patient visit (45+ min) | 15 | $1,617 | $108 |
| Long return visit (40+ min) | 13 | $1,594 | $94 |
2016: 2 services
| Return visit (30+ min) | 109 | $15,793 | $63 |
| Long return visit (40+ min) | 22 | $2,948 | $92 |
2015: 3 services
| Return visit (30+ min) | 91 | $13,582 | $65 |
| Long return visit (40+ min) | 48 | $5,978 | $95 |
| New patient visit (60+ min) | 21 | $2,693 | $128 |
2014: 3 services
| Long return visit (40+ min) | 61 | $10,405 | $85 |
| Return visit (30+ min) | 44 | $4,824 | $67 |
| New patient visit (60+ min) | 17 | $2,427 | $143 |
2013: 4 services
| Long return visit (40+ min) | 64 | $13,315 | $94 |
| Return visit (30+ min) | 41 | $3,667 | $57 |
| New patient visit (60+ min) | 21 | $3,045 | $145 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 12 | $1,057 | $34 |
Medicaid work
$7,418 in 2024
Medicaid paid $7,418 for 84 billed services this clinician did in 2024, up to 17 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Long return visit (40+ min) | 84 | $7,418 |
| 2024 | 84 | 1 | 17 | $7,418 |
| 2023 | 142 | 2 | 22 | $8,355 |
| 2022 | 174 | 2 | 20 | $8,716 |
| 2021 | 131 | 2 | 19 | $6,265 |
| 2020 | 192 | 1 | 29 | $7,838 |
| 2019 | 190 | 1 | 27 | $8,070 |
| 2018 | 176 | 1 | 26 | $8,404 |
See the largest Medicaid services in earlier years
2023
| Long return visit (40+ min) | 99 | $6,271 |
| Return visit (30+ min) | 43 | $2,084 |
2022
| Return visit (30+ min) | 114 | $5,161 |
| Long return visit (40+ min) | 60 | $3,555 |
2021
| Return visit (30+ min) | 90 | $4,058 |
| Long return visit (40+ min) | 41 | $2,208 |
2020
| Return visit (30+ min) | 192 | $7,838 |
2019
| Return visit (30+ min) | 190 | $8,070 |
2018
| Return visit (30+ min) | 176 | $8,404 |
Drugs they prescribed that Part D paid
$1,479,969
Pharmacies billed $1,479,969 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 2,445) in 2024. At or below the middle of the specialty; the typical endocrinology clinician is at 0%.
1,041 generic and 1,226 brand-name prescriptions · $1,479,969 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Mounjaro | 223 | $335,881 | $1,506 |
| Ozempic | 123 | $221,047 | $1,797 |
| Jardiance | 166 | $212,254 | $1,279 |
| Trulicity | 88 | $159,615 | $1,814 |
| Rybelsus | 57 | $76,260 | $1,338 |
See all 49 drugs
| Mounjaro | 223 | $335,881 | $1,506 |
| Ozempic | 123 | $221,047 | $1,797 |
| Jardiance | 166 | $212,254 | $1,279 |
| Trulicity | 88 | $159,615 | $1,814 |
| Rybelsus | 57 | $76,260 | $1,338 |
| Afrezza | 35 | $61,609 | $1,760 |
| Toujeo Max Solostar | 24 | $40,393 | $1,683 |
| Synjardy Xr | 27 | $38,494 | $1,426 |
| Tresiba Flextouch U-200 | 25 | $37,418 | $1,497 |
| Januvia | 23 | $32,734 | $1,423 |
| Omnipod 5 Dexg7g6 Pods (Gen 5) | 16 | $27,874 | $1,742 |
| Vascepa | 19 | $13,999 | $737 |
| Fiasp | 13 | $11,292 | $869 |
| Toujeo Solostar | 13 | $10,224 | $786 |
| Basaglar Kwikpen U-100 | 28 | $9,817 | $351 |
| Tresiba Flextouch U-100 | 17 | $9,033 | $531 |
| Nano 2nd Gen Pen Needle | 82 | $7,591 | $93 |
| Novolog | 17 | $6,477 | $381 |
| Humalog Kwikpen U-100 | 18 | $5,448 | $303 |
| Novolog Mix 70-30 Flexpen | 23 | $4,922 | $214 |
| Lantus Solostar | 37 | $4,100 | $111 |
| Insulin Lispro Kwikpen U-100 | 20 | $3,816 | $191 |
| Novolog Flexpen | 19 | $3,543 | $186 |
| Insulin Glargine-Yfgn | 17 | $2,327 | $137 |
| Atorvastatin | 135 | $1,731 | $13 |
| Rosuvastatin | 56 | $1,328 | $24 |
| Metformin | 135 | $1,138 | $8 |
| Levothyroxine | 77 | $1,069 | $14 |
| Colesevelam | 11 | $1,055 | $96 |
| Droplet Pen Needle | 11 | $1,010 | $92 |
| Pioglitazone | 60 | $911 | $15 |
| Metformin Hcl Er | 73 | $859 | $12 |
| Levemir Flexpen | 15 | $811 | $54 |
| Ultra-Fine Mini Pen Needle | 13 | $716 | $55 |
| Ezetimibe | 11 | $556 | $51 |
| Glipizide Er | 21 | $516 | $25 |
| Losartan | 69 | $493 | $7 |
| Glipizide | 60 | $451 | $8 |
| Chlorthalidone | 29 | $354 | $12 |
| Amlodipine Besylate | 38 | $298 | $8 |
| Spironolactone | 26 | $287 | $11 |
| Alendronate | 14 | $236 | $17 |
| Glimepiride | 14 | $233 | $17 |
| Gabapentin | 11 | $195 | $18 |
| Lisinopril | 18 | $145 | $8 |
| Furosemide | 15 | $63 | $4 |
| Pravastatin | 15 | $54 | $4 |
| Hydrochlorothiazide | 11 | $24 | $2 |
| Allopurinol | 14 | $24 | $2 |
Year by year
| 2024 | 2,445 | 193 | 0% (0) | 50% | $1,479,969 |
| 2023 | 2,334 | 184 | 0% (0) | 48% | $1,605,720 |
| 2022 | 2,248 | 186 | 0% (0) | 47% | $1,401,251 |
| 2021 | 2,161 | 182 | 0% (0) | 49% | $1,258,433 |
| 2020 | 1,835 | 155 | 0% (0) | 52% | $925,774 |
| 2019 | 1,779 | 129 | 0% (0) | 52% | $790,208 |
| 2018 | 1,673 | 119 | 0% (0) | 49% | $665,116 |
| 2017 | 1,685 | 114 | None | 47% | $556,951 |
| 2016 | 1,696 | 132 | 0% (0) | 48% | $509,577 |
| 2015 | 1,518 | 105 | None | 43% | $326,447 |
| 2014 | 915 | 74 | 0% (0) | 43% | $146,989 |
| 2013 | 718 | 69 | 0% (0) | 47% | $113,275 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 43 drugs
| Trulicity | 164 | $288,859 | $1,761 |
| Jardiance | 153 | $229,697 | $1,501 |
| Ozempic | 116 | $205,592 | $1,772 |
| Mounjaro | 84 | $145,559 | $1,733 |
| Rybelsus | 51 | $80,896 | $1,586 |
| Tresiba Flextouch U-200 | 32 | $52,293 | $1,634 |
| Januvia | 37 | $50,073 | $1,353 |
| Novolog Flexpen | 45 | $48,732 | $1,083 |
| Afrezza | 23 | $34,764 | $1,511 |
| Novolog Mix 70-30 Flexpen | 28 | $33,748 | $1,205 |
| Synjardy Xr | 23 | $32,603 | $1,418 |
| Humulin R U-500 Kwikpen | 21 | $31,471 | $1,499 |
| Fiasp Flextouch | 11 | $28,291 | $2,572 |
| Omnipod 5 G6 Pods (Gen 5) | 20 | $26,482 | $1,324 |
| Humalog Kwikpen U-100 | 16 | $20,873 | $1,305 |
| Novolog | 17 | $20,461 | $1,204 |
| Lantus Solostar | 27 | $18,588 | $688 |
| Toujeo Solostar | 12 | $16,568 | $1,381 |
| Humalog Mix 75-25 Kwikpen | 11 | $13,053 | $1,187 |
| Insulin Aspart | 18 | $12,945 | $719 |
| Basaglar Kwikpen U-100 | 30 | $12,263 | $409 |
| Nano 2nd Gen Pen Needle | 61 | $6,249 | $102 |
| Atorvastatin | 130 | $2,938 | $23 |
| Valsartan | 19 | $2,269 | $119 |
| Metformin | 126 | $2,259 | $18 |
| Rosuvastatin | 65 | $2,088 | $32 |
| Insulin Glargine-Yfgn | 13 | $1,933 | $149 |
| Pioglitazone | 75 | $1,927 | $26 |
| Ultra-Fine Nano Pen Needle | 16 | $1,904 | $119 |
| Metformin Hcl Er | 72 | $1,712 | $24 |
| Levothyroxine | 87 | $1,525 | $18 |
| Glipizide | 70 | $1,194 | $17 |
| Losartan | 67 | $1,169 | $17 |
| Chlorthalidone | 27 | $679 | $25 |
| Glipizide Er | 19 | $633 | $33 |
| Ezetimibe | 11 | $623 | $57 |
| Nifedipine Er | 11 | $550 | $50 |
| Amlodipine Besylate | 36 | $519 | $14 |
| Spironolactone | 23 | $424 | $18 |
| Gabapentin | 13 | $212 | $16 |
| Simvastatin | 11 | $190 | $17 |
| Lisinopril | 25 | $171 | $7 |
| Hydrochlorothiazide | 19 | $147 | $8 |
2022: 44 drugs
| Trulicity | 229 | $331,721 | $1,449 |
| Ozempic | 111 | $206,008 | $1,856 |
| Jardiance | 144 | $205,310 | $1,426 |
| Tresiba Flextouch U-200 | 47 | $67,738 | $1,441 |
| Novolog Flexpen | 46 | $62,009 | $1,348 |
| Januvia | 34 | $46,015 | $1,353 |
| Rybelsus | 38 | $44,684 | $1,176 |
| Humulin R U-500 Kwikpen | 25 | $40,170 | $1,607 |
| Synjardy Xr | 27 | $37,963 | $1,406 |
| Lantus Solostar | 56 | $29,940 | $535 |
| Humalog Kwikpen U-100 | 20 | $22,469 | $1,123 |
| Novolog | 13 | $17,701 | $1,362 |
| Novolog Mix 70-30 | 12 | $15,564 | $1,297 |
| Basaglar Kwikpen U-100 | 23 | $10,588 | $460 |
| Levemir Flextouch | 20 | $9,139 | $457 |
| Toujeo Solostar | 13 | $7,851 | $604 |
| Lantus | 12 | $6,492 | $541 |
| Nano 2nd Gen Pen Needle | 51 | $5,898 | $116 |
| Comfort Ez Pen Needle | 21 | $3,049 | $145 |
| Rosuvastatin | 51 | $2,775 | $54 |
| Atorvastatin | 143 | $2,190 | $15 |
| Levothyroxine | 78 | $1,969 | $25 |
| Metformin | 145 | $1,826 | $13 |
| Droplet Pen Needle | 12 | $1,576 | $131 |
| Chlorthalidone | 27 | $1,162 | $43 |
| Repaglinide | 14 | $1,137 | $81 |
| Ultra-Fine Nano Pen Needle | 12 | $1,120 | $93 |
| Valsartan | 14 | $963 | $69 |
| Metformin Hcl Er | 67 | $956 | $14 |
| Ultra-Fine Short Pen Needle | 12 | $947 | $79 |
| Glipizide | 69 | $812 | $12 |
| Losartan | 54 | $742 | $14 |
| Pioglitazone | 59 | $727 | $12 |
| Glimepiride | 18 | $526 | $29 |
| Glipizide Er | 24 | $456 | $19 |
| Spironolactone | 16 | $350 | $22 |
| Gabapentin | 17 | $346 | $20 |
| Metoprolol | 13 | $299 | $23 |
| Alendronate | 14 | $204 | $15 |
| Simvastatin | 12 | $141 | $12 |
| Amlodipine Besylate | 31 | $120 | $4 |
| Fenofibrate | 12 | $115 | $10 |
| Lisinopril | 18 | $88 | $5 |
| Fluconazole | 12 | $27 | $2 |
2021: 40 drugs
| Trulicity | 258 | $341,031 | $1,322 |
| Jardiance | 129 | $160,371 | $1,243 |
| Ozempic | 68 | $113,228 | $1,665 |
| Novolog Flexpen | 59 | $74,683 | $1,266 |
| Tresiba Flextouch U-200 | 44 | $54,974 | $1,249 |
| Humulin R U-500 Kwikpen | 31 | $46,064 | $1,486 |
| Januvia | 41 | $45,228 | $1,103 |
| Lantus Solostar | 50 | $30,736 | $615 |
| Victoza 3-Pak | 16 | $29,927 | $1,870 |
| Humalog Kwikpen U-100 | 20 | $26,276 | $1,314 |
| Toujeo Solostar | 35 | $26,214 | $749 |
| Humalog | 16 | $21,880 | $1,367 |
| Rybelsus | 19 | $19,077 | $1,004 |
| Levemir Flextouch | 25 | $17,806 | $712 |
| Synjardy Xr | 11 | $17,453 | $1,587 |
| Novolog Mix 70-30 | 11 | $13,951 | $1,268 |
| Lantus | 17 | $9,301 | $547 |
| Novolog Mix 70-30 Flexpen | 11 | $7,936 | $721 |
| Nano 2nd Gen Pen Needle | 67 | $7,259 | $108 |
| Basaglar Kwikpen U-100 | 15 | $6,870 | $458 |
| Insulin Lispro Kwikpen U-100 | 15 | $3,906 | $260 |
| Rosuvastatin | 41 | $2,124 | $52 |
| Atorvastatin | 124 | $1,860 | $15 |
| Metformin | 159 | $1,694 | $11 |
| Levothyroxine | 64 | $1,621 | $25 |
| Comfort Ez Pen Needle | 13 | $1,403 | $108 |
| Chlorthalidone | 24 | $1,139 | $47 |
| Ultra-Fine Nano Pen Needle | 13 | $1,089 | $84 |
| Glipizide | 68 | $790 | $12 |
| Metformin Hcl Er | 68 | $749 | $11 |
| Lisinopril | 37 | $448 | $12 |
| Losartan | 38 | $400 | $11 |
| Pioglitazone | 27 | $368 | $14 |
| Spironolactone | 13 | $363 | $28 |
| Glimepiride | 16 | $344 | $22 |
| Gabapentin | 20 | $333 | $17 |
| Metoprolol | 13 | $292 | $22 |
| Amlodipine Besylate | 37 | $253 | $7 |
| Alendronate | 15 | $208 | $14 |
| Hydrochlorothiazide | 13 | $97 | $7 |
2020: 41 drugs
| Trulicity | 179 | $211,548 | $1,182 |
| Jardiance | 75 | $96,639 | $1,289 |
| Ozempic | 50 | $70,967 | $1,419 |
| Novolog Flexpen | 65 | $68,974 | $1,061 |
| Tresiba Flextouch U-200 | 50 | $57,326 | $1,147 |
| Humulin R U-500 Kwikpen | 33 | $50,573 | $1,533 |
| Victoza 3-Pak | 27 | $45,202 | $1,674 |
| Lantus Solostar | 55 | $31,072 | $565 |
| Humalog Kwikpen U-100 | 32 | $28,349 | $886 |
| Januvia | 32 | $24,894 | $778 |
| Novolog | 20 | $15,953 | $798 |
| Toujeo Solostar | 27 | $15,518 | $575 |
| Lantus | 34 | $14,159 | $416 |
| Novolog Mix 70-30 Flexpen | 22 | $13,433 | $611 |
| Vascepa | 14 | $8,477 | $606 |
| Ultra-Fine Nano Pen Needle | 75 | $5,951 | $79 |
| Basaglar Kwikpen U-100 | 17 | $5,003 | $294 |
| Comfort Ez Pen Needle | 30 | $3,157 | $105 |
| Nano 2nd Gen Pen Needle | 22 | $1,727 | $79 |
| Levothyroxine | 61 | $1,668 | $27 |
| Chlorthalidone | 26 | $1,648 | $63 |
| Ultra-Fine Mini Pen Needle | 20 | $1,603 | $80 |
| Ultracare Pen Needle | 11 | $1,466 | $133 |
| Metformin Hcl Er | 62 | $1,331 | $21 |
| Rosuvastatin | 21 | $1,314 | $63 |
| Atorvastatin | 76 | $1,306 | $17 |
| Metformin | 98 | $940 | $10 |
| Pen Needles | 13 | $814 | $63 |
| Glipizide | 46 | $664 | $14 |
| Hydrocortisone | 18 | $661 | $37 |
| Spironolactone | 13 | $495 | $38 |
| Lisinopril | 27 | $422 | $16 |
| Gabapentin | 32 | $406 | $13 |
| Losartan | 27 | $402 | $15 |
| Glimepiride | 15 | $364 | $24 |
| Pioglitazone | 16 | $297 | $19 |
| Alendronate | 16 | $221 | $14 |
| Simvastatin | 12 | $207 | $17 |
| Amlodipine Besylate | 31 | $201 | $6 |
| Insulin | 12 | $142 | $12 |
| Hydrochlorothiazide | 13 | $103 | $8 |
2019: 45 drugs
| Trulicity | 114 | $126,312 | $1,108 |
| Victoza 3-Pak | 63 | $81,629 | $1,296 |
| Jardiance | 72 | $72,467 | $1,006 |
| Tresiba Flextouch U-200 | 50 | $48,532 | $971 |
| Humulin R U-500 Kwikpen | 28 | $44,855 | $1,602 |
| Novolog Flexpen | 50 | $36,995 | $740 |
| Humalog Kwikpen U-100 | 37 | $27,216 | $736 |
| Ozempic | 31 | $27,017 | $872 |
| Lantus Solostar | 49 | $26,544 | $542 |
| Januvia | 34 | $19,773 | $582 |
| Humalog Mix 50-50 Kwikpen | 17 | $18,791 | $1,105 |
| Toujeo Max Solostar | 22 | $18,404 | $837 |
| Novolog | 25 | $18,279 | $731 |
| Humulin 70/30 Kwikpen | 12 | $12,089 | $1,007 |
| Farxiga | 12 | $12,012 | $1,001 |
| Novolog Mix 70-30 Flexpen | 22 | $11,931 | $542 |
| Metformin Er Osmotic | 13 | $11,751 | $904 |
| Toujeo Solostar | 16 | $11,065 | $692 |
| Invokana | 13 | $9,518 | $732 |
| Lantus | 21 | $9,201 | $438 |
| Basaglar Kwikpen U-100 | 18 | $8,141 | $452 |
| Ultra-Fine Nano Pen Needle | 97 | $6,673 | $69 |
| Levemir | 11 | $6,232 | $567 |
| Janumet Xr | 13 | $5,825 | $448 |
| Comfort Ez Pen Needle | 32 | $3,253 | $102 |
| Chlorthalidone | 35 | $1,753 | $50 |
| Synthroid | 25 | $1,663 | $67 |
| Levothyroxine | 76 | $1,456 | $19 |
| Atorvastatin | 58 | $1,208 | $21 |
| Ultra-Fine Short Pen Needle | 11 | $1,142 | $104 |
| Easy Comfort Pen Needles | 13 | $1,093 | $84 |
| Metformin Hcl Er | 56 | $969 | $17 |
| Metformin | 102 | $800 | $8 |
| Glipizide | 52 | $718 | $14 |
| Hydrocortisone | 14 | $631 | $45 |
| Losartan | 33 | $428 | $13 |
| Rosuvastatin | 11 | $412 | $37 |
| Glimepiride | 15 | $372 | $25 |
| Gabapentin | 23 | $339 | $15 |
| Lisinopril | 28 | $309 | $11 |
| Amlodipine Besylate | 26 | $233 | $9 |
| Insulin | 13 | $190 | $15 |
| Pioglitazone | 11 | $183 | $17 |
| Simvastatin | 15 | $177 | $12 |
| Benazepril | 11 | $105 | $10 |
2018: 45 drugs
| Victoza 3-Pak | 65 | $75,162 | $1,156 |
| Humulin R U-500 Kwikpen | 51 | $71,925 | $1,410 |
| Humalog Kwikpen U-100 | 49 | $48,159 | $983 |
| Trulicity | 38 | $46,523 | $1,224 |
| Tresiba Flextouch U-200 | 46 | $42,437 | $923 |
| Lantus Solostar | 61 | $34,294 | $562 |
| Victoza 2-Pak | 27 | $27,830 | $1,031 |
| Humalog Mix 50-50 Kwikpen | 22 | $25,013 | $1,137 |
| Novolog Flexpen | 22 | $23,105 | $1,050 |
| Januvia | 31 | $20,802 | $671 |
| Jardiance | 31 | $20,348 | $656 |
| Humalog Mix 50-50 | 14 | $18,697 | $1,336 |
| Invokana | 18 | $17,689 | $983 |
| Novolog | 15 | $12,732 | $849 |
| Bydureon Bcise | 18 | $12,237 | $680 |
| Ozempic | 13 | $9,351 | $719 |
| Tradjenta | 11 | $6,998 | $636 |
| Janumet Xr | 13 | $6,542 | $503 |
| Lantus | 12 | $6,446 | $537 |
| Basaglar Kwikpen U-100 | 20 | $6,416 | $321 |
| Ultra-Fine Nano Pen Needle | 117 | $6,223 | $53 |
| Humulin 70-30 | 12 | $5,625 | $469 |
| Levemir | 11 | $4,067 | $370 |
| Tirosint | 18 | $3,246 | $180 |
| Levothyroxine | 80 | $1,674 | $21 |
| Synthroid | 18 | $1,261 | $70 |
| Atorvastatin | 64 | $1,031 | $16 |
| Metformin Hcl Er | 57 | $994 | $17 |
| Unifine Pentips | 22 | $914 | $42 |
| Metformin | 86 | $820 | $10 |
| Chlorthalidone | 23 | $784 | $34 |
| Glipizide | 76 | $736 | $10 |
| Bupropion Hcl Sr | 12 | $716 | $60 |
| Hydrocortisone | 12 | $543 | $45 |
| Potassium Chloride | 11 | $506 | $46 |
| Glimepiride | 15 | $453 | $30 |
| Simvastatin | 13 | $333 | $26 |
| Gabapentin | 19 | $233 | $12 |
| Lisinopril | 25 | $220 | $9 |
| Losartan | 21 | $212 | $10 |
| Amlodipine Besylate | 29 | $196 | $7 |
| Pioglitazone | 15 | $138 | $9 |
| Benazepril | 12 | $81 | $7 |
| Hydrochlorothiazide | 13 | $77 | $6 |
| Furosemide | 17 | $60 | $4 |
2017: 43 drugs
| Victoza 3-Pak | 77 | $83,957 | $1,090 |
| Humulin R U-500 Kwikpen | 37 | $43,262 | $1,169 |
| Lantus Solostar | 77 | $38,353 | $498 |
| Humulin R U-500 | 16 | $35,402 | $2,213 |
| Januvia | 44 | $27,043 | $615 |
| Victoza 2-Pak | 44 | $25,991 | $591 |
| Humalog Kwikpen U-100 | 38 | $25,397 | $668 |
| Tresiba Flextouch U-200 | 25 | $24,952 | $998 |
| Trulicity | 34 | $24,860 | $731 |
| Humalog Mix 50-50 Kwikpen | 14 | $21,826 | $1,559 |
| Jardiance | 48 | $21,429 | $446 |
| Novolog Flexpen | 19 | $16,491 | $868 |
| Novolog | 17 | $13,568 | $798 |
| Bydureon | 19 | $11,731 | $617 |
| Invokana | 18 | $10,966 | $609 |
| Lantus | 22 | $10,200 | $464 |
| Humalog Mix 75-25 | 11 | $9,622 | $875 |
| Novolog Mix 70-30 Flexpen | 12 | $8,174 | $681 |
| Janumet Xr | 18 | $7,065 | $392 |
| Ultra-Fine Nano Pen Needle | 113 | $6,398 | $57 |
| Levemir Flextouch | 12 | $4,827 | $402 |
| Tirosint | 28 | $4,497 | $161 |
| Levothyroxine | 57 | $1,526 | $27 |
| Synthroid | 20 | $1,475 | $74 |
| Atorvastatin | 66 | $1,342 | $20 |
| Metformin Hcl Er | 56 | $1,149 | $21 |
| Glipizide | 69 | $749 | $11 |
| Metformin | 77 | $682 | $9 |
| Bupropion Hcl Sr | 15 | $665 | $44 |
| Pen Needle | 15 | $600 | $40 |
| Insulin | 22 | $585 | $27 |
| Unifine Pentips | 19 | $530 | $28 |
| Ultra-Fine Short Pen Needle | 12 | $465 | $39 |
| Potassium Chloride | 14 | $440 | $31 |
| Insulin | 16 | $368 | $23 |
| Glimepiride | 25 | $267 | $11 |
| Lisinopril | 39 | $253 | $6 |
| Losartan | 37 | $219 | $6 |
| Carvedilol | 13 | $184 | $14 |
| Pioglitazone | 17 | $171 | $10 |
| Amlodipine Besylate | 23 | $137 | $6 |
| Furosemide | 21 | $95 | $5 |
| Hydrochlorothiazide | 14 | $81 | $6 |
2016: 41 drugs
| Victoza 3-Pak | 99 | $86,182 | $871 |
| Januvia | 51 | $34,867 | $684 |
| Lantus Solostar | 62 | $30,507 | $492 |
| Humalog Mix 50-50 Kwikpen | 27 | $29,104 | $1,078 |
| Humulin R U-500 | 17 | $28,667 | $1,686 |
| Victoza 2-Pak | 48 | $25,530 | $532 |
| Humalog Kwikpen U-100 | 39 | $23,044 | $591 |
| Humulin R U-500 Kwikpen | 18 | $22,231 | $1,235 |
| Novolog Flexpen | 23 | $20,050 | $872 |
| Humalog Mix 50-50 | 16 | $18,115 | $1,132 |
| Jardiance | 40 | $17,630 | $441 |
| Novolog | 28 | $15,764 | $563 |
| Tresiba Flextouch U-200 | 13 | $14,118 | $1,086 |
| Trulicity | 13 | $11,316 | $870 |
| Invokana | 13 | $10,007 | $770 |
| Lantus | 26 | $9,523 | $366 |
| Levemir Flextouch | 17 | $6,647 | $391 |
| Bd Ultra-Fine Pen Needle | 102 | $5,443 | $53 |
| Tirosint | 25 | $4,816 | $193 |
| Janumet Xr | 11 | $4,131 | $376 |
| Synthroid | 38 | $2,532 | $67 |
| Metformin Hcl Er | 59 | $1,649 | $28 |
| Levothyroxine | 58 | $1,444 | $25 |
| Atorvastatin | 78 | $1,433 | $18 |
| Glipizide | 84 | $939 | $11 |
| Metformin | 71 | $609 | $9 |
| Repaglinide | 14 | $518 | $37 |
| Bupropion Hcl Sr | 14 | $475 | $34 |
| Pen Needle | 14 | $460 | $33 |
| Insulin | 13 | $342 | $26 |
| Metoprolol | 16 | $327 | $20 |
| Potassium Chloride | 16 | $323 | $20 |
| Insulin | 13 | $306 | $24 |
| Glimepiride | 23 | $291 | $13 |
| Lisinopril | 50 | $283 | $6 |
| Amlodipine Besylate | 29 | $198 | $7 |
| Losartan | 34 | $184 | $5 |
| Pioglitazone | 13 | $144 | $11 |
| Simvastatin | 11 | $97 | $9 |
| Benazepril | 13 | $76 | $6 |
| Topiramate | 13 | $52 | $4 |
2015: 38 drugs
| Victoza 3-Pak | 63 | $45,146 | $717 |
| Januvia | 54 | $27,474 | $509 |
| Humulin R U-500 | 19 | $24,260 | $1,277 |
| Novolog Flexpen | 23 | $22,770 | $990 |
| Humalog Mix 50-50 | 22 | $21,560 | $980 |
| Tradjenta | 50 | $20,286 | $406 |
| Lantus Solostar | 54 | $18,922 | $350 |
| Humalog Mix 50-50 Kwikpen | 23 | $18,477 | $803 |
| Lantus | 37 | $14,627 | $395 |
| Humalog Kwikpen U-100 | 29 | $13,506 | $466 |
| Victoza 2-Pak | 23 | $9,861 | $429 |
| Invokana | 14 | $6,264 | $447 |
| Bydureon | 12 | $6,114 | $510 |
| Riomet | 11 | $5,141 | $467 |
| Bd Ultra-Fine Pen Needle | 76 | $3,427 | $45 |
| Synthroid | 38 | $1,910 | $50 |
| Atorvastatin | 90 | $1,618 | $18 |
| Metformin Hcl Er | 63 | $1,324 | $21 |
| Levothyroxine | 50 | $1,181 | $24 |
| Repaglinide | 11 | $667 | $61 |
| Glipizide | 89 | $602 | $7 |
| Metoprolol | 16 | $590 | $37 |
| Pravastatin | 15 | $545 | $36 |
| Insulin | 19 | $469 | $25 |
| Metformin | 62 | $409 | $7 |
| Glimepiride | 32 | $333 | $10 |
| Potassium Chloride | 14 | $308 | $22 |
| Lisinopril | 49 | $247 | $5 |
| Insulin | 15 | $237 | $16 |
| Spironolactone | 24 | $216 | $9 |
| Losartan | 38 | $212 | $6 |
| Pioglitazone | 15 | $184 | $12 |
| Simvastatin | 30 | $181 | $6 |
| Lovastatin | 11 | $180 | $16 |
| Amlodipine Besylate | 27 | $133 | $5 |
| Insulin | 11 | $103 | $9 |
| Furosemide | 13 | $73 | $6 |
| Atenolol | 12 | $44 | $4 |
2014: 30 drugs
| Januvia | 36 | $19,730 | $548 |
| Humalog Mix 50-50 | 22 | $18,400 | $836 |
| Humalog | 44 | $16,764 | $381 |
| Tradjenta | 37 | $12,185 | $329 |
| Humalog Mix 75-25 | 16 | $10,112 | $632 |
| Lantus Solostar | 31 | $9,517 | $307 |
| Victoza 3-Pak | 13 | $8,663 | $666 |
| Victoza 2-Pak | 15 | $5,743 | $383 |
| Lantus | 13 | $4,441 | $342 |
| Novolog | 12 | $2,204 | $184 |
| Synthroid | 36 | $1,698 | $47 |
| Bd Ultra-Fine Pen Needle | 29 | $1,250 | $43 |
| Metformin Hcl Er | 43 | $718 | $17 |
| Glipizide-Metformin | 11 | $653 | $59 |
| Atorvastatin | 39 | $622 | $16 |
| Glipizide | 78 | $605 | $8 |
| Levothyroxine | 25 | $521 | $21 |
| Metformin | 31 | $419 | $14 |
| Losartan | 56 | $417 | $7 |
| Pravastatin | 13 | $375 | $29 |
| Metoprolol | 14 | $323 | $23 |
| Glipizide Xl | 13 | $318 | $24 |
| Insulin | 11 | $212 | $19 |
| Spironolactone | 19 | $204 | $11 |
| Simvastatin | 22 | $189 | $9 |
| Glimepiride | 13 | $178 | $14 |
| Gabapentin | 11 | $137 | $12 |
| Lisinopril | 15 | $75 | $5 |
| Furosemide | 16 | $68 | $4 |
| Atenolol | 14 | $62 | $4 |
2013: 24 drugs
| Humulin R | 14 | $19,041 | $1,360 |
| Januvia | 39 | $14,740 | $378 |
| Humalog Mix 50-50 | 22 | $12,190 | $554 |
| Humalog | 43 | $12,111 | $282 |
| Humalog Mix 75-25 | 14 | $7,123 | $509 |
| Lantus Solostar | 23 | $5,750 | $250 |
| Lantus | 24 | $5,329 | $222 |
| Novolog | 20 | $5,267 | $263 |
| Tradjenta | 18 | $4,484 | $249 |
| Bd Ultra-Fine Pen Needle | 31 | $979 | $32 |
| Synthroid | 21 | $788 | $38 |
| Insulin | 18 | $518 | $29 |
| Topiramate | 22 | $489 | $22 |
| Metformin | 24 | $481 | $20 |
| Glipizide | 58 | $478 | $8 |
| Glyburide | 13 | $313 | $24 |
| Hydrochlorothiazide | 12 | $310 | $26 |
| Losartan | 18 | $262 | $15 |
| Metformin Hcl Er | 19 | $251 | $13 |
| Simvastatin | 14 | $214 | $15 |
| Levothyroxine | 15 | $165 | $11 |
| Amlodipine Besylate | 17 | $129 | $8 |
| Glimepiride | 11 | $102 | $9 |
| Atenolol | 13 | $58 | $4 |
Money from drug and device companies
$298 in 2025
| 2025 | 2 | 2 | None | $298 |
| 2024 | 2 | 10 | $11,813 | $17,065 |
| 2022 | 1 | 1 | None | $12 |
| 2020 | 2 | 3 | $1,748 | $1,784 |
| 2019 | 6 | 12 | $6,912 | $8,771 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Dexcom | Dexcom G6 Transmitter | $153 | 1 payment
|
| Sequel Med Tech | Twiist | $145 | 1 payment
|
See all 2 published payments
| Dexcom | Meals · 2025-10-23 | Dexcom G6 Transmitter | $153 |
| Sequel Med Tech | Meals · 2025-09-15 | Twiist | $145 |
See earlier years (2024, 2022, 2020, 2019)
2024: $17,065
| Novo Nordisk | None | $16,932 | 9 payments
|
| Abbott Laboratories | Freestyle Libre 3 | $133 | 1 payment
|
2022: $12
| Lilly USA | None | $12 | 1 payment
|
2020: $1,784
| Bayer HealthCare Pharmaceuticals | Non-Covered | $1,748 | 1 payment
|
| Dendreon Pharmaceuticals | Provenge | $36 | 2 payments
|
2019: $8,771
| Sanofi-Aventis U.S. | No Product Discussed | $8,330 | 6 payments
|
| Tandem Diabetes Care | T-Slim Insulin Pump | $140 | 2 payments
|
| Mannkind | Afrezza | $119 | 1 payment
|
| AbbVie | Synthroid | $102 | 1 payment
|
| Senseonics | Eversense | $51 | 1 payment
|
| Dendreon Pharmaceuticals | Provenge | $29 | 1 payment
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| Janssen Research & Development, LLC · A Randomized Double Blind, Placebo Group, Two-Arm, Multicenter Study To Assess Efficacy of Canagliflozin on End Stage Kidney Disease and Vascular Death in Subjects With Type 2 Diabetes Mellitus and Nephropathy · 2019 | Their institution | $894 |
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 76.5 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1083894844
- Licence
- CA A75251California A75251: Current · expires 2028-07-31
- Trained
- University of California, San Diego School of Medicine, 1998
- Group
- Stanford Health Care
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- Yes
- Taxonomy
- Federal specialty code 207RE0101X (207RE0101X)
- Mailing address
- 300 Pasteur Dr Rm S025, Stanford, CA, 94305
- NPI first listed
- 2007-11-09
- NPI last updated
- 2024-04-25
- NPI record certified
- 2024-04-25
This is when the NPI record was last certified, not a medical board exam.